Mutational Signatures Of DDT: The Role Of A Controversial Persistent Endocrine Disrupting Pollutant On Prostate Cancer Aetiology
Funder
National Health and Medical Research Council
Funding Amount
$991,000.00
Summary
No carcinogen or prevention has been identified for prostate cancer (PCa). As carcinogens are commonly mutagens, we will use genomic interrogation to determine if extensive use of the hormone-disrupting pesticide DDT during the 40's to late 80's increased PCa globally. Having access to prostate tumours from men with biochemically confirmed lifelong DDT-exposure, will provide a measurable genomic signature to evaluate the impact of DDT globally, including Australia.
Understanding Tumour Plasticity And The Microenvironment Using Single-cell Technologies To Identify Novel Targets For Metastatic Castration-resistant Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$653,578.00
Summary
Most prostate cancer patients respond well to treatment, but some develop metastatic disease and respond poorly. During metastasis the cancer spreads to multiple organs and new combinations of genes become activated, making it difficult to develop new treatments. We will investigate these patterns of activation of genes in metastatic samples and how the immune system interacts with the cancer. We will use computational models to identify new drug targets and evaluate immunotherapy as an option.
Presentation Of Metabolite Antigens By MR1 Molecules: A Fundamental System Of Immune Priming
Funder
National Health and Medical Research Council
Funding Amount
$883,832.00
Summary
Our immune system constantly monitors our body for disease-causing microbes, such as bacteria that cause illnesses like pneumonia or tuberculosis. Our cells have a molecular alarm-system called 'MR1' which alerts white blood cells that an infection by microbes is occurring, however this process is not well understood. This grant will allow me to discover the cells and molecular pathways that govern the MR1 alarm system, which may lead to new treatments against common diseases in our community.
Engineering CYP17A1 Inhibitors For Castrate-resistant Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$519,428.00
Summary
As prostate cancer progresses it becomes resistant to first line treatments and the current second line treatments have untoward side effects. This proposal will provide proof of principal for new selective drugs to be developed. We propose an innovative strategy to develop new selective drugs for the treatment of prostate cancer. This new therapeutic approach will identify new compounds for patients specifically with castrate sensitive and resistant prostate cancer.
Dendritic cells are essential components of our immune systems. They are located throughout our body and provide the first line of defence against invading microbes. Dendritic cells sense the invader and send out signals to recruit our immune cells to the site of infection. Our research aims to understand how our dendritic cell network is set up and how it functions to promote our immune health.
Identifying Molecular Machinery In Dendritic Cells.
Funder
National Health and Medical Research Council
Funding Amount
$687,500.00
Summary
Vaccines invoke immune responses that will protect a vaccinated host if they encounter infection. Vaccines can also be deployed to fight cancer. 'Dendritic cells' are the key immune cell responsible for vaccine immunity. While dendritic cells are pivotal to initiating vaccination, little is known about their internal machinery. This research proposal will identify new machinery for dendritic cell vaccine immunity that will serve as therapeutic targets to boost vaccination.
Molecular Dissection Of Allergen Sensitisation And Immunotherapy: Direct Application To Precision Medicine In Treatment Of Asthma
Funder
National Health and Medical Research Council
Funding Amount
$1,270,097.00
Summary
Asthma is a major global health burden with huge socioeconomic impact. Most asthmatic patients are allergic. Allergen immunotherapy is the only treatment to alter the natural disease course, but does not work in many treated patients, and robust laboratory biomarkers for patient selection and immune monitoring of treatment success are lacking. Therefore, allergen immunotherapy is not offered to most patients who then rely on medications indefinitely. This research will address these needs.